Activation of the RON was shown to confer tamoxifen resistance in breast cancer cells, and HGFL-mediated RON activation can partially reverse tamoxifen-induced cytotoxicity in human and mouse breast cancer cell lines [102]. Here, MST1R is linked to breast carcinoma.